Arcus Biosciences Inc (RCUS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $2.43B
Last updated: Nov 17, 2026 at 4:20 PM ET
Arcus Biosciences Inc (RCUS) Statistics
Arcus Biosciences (RCUS) has a market cap of $2.43B and an enterprise value of $2.38B. It kept -453.00% of revenue as net income over the last 12 months. Its share count is up 19.62% from a year earlier.
Total Valuation
Enterprise value is 2.02% below the market cap, as cash exceeds debt.
| Market Cap | $2.43B |
|---|---|
| Enterprise Value | $2.38B |
| Latest price (Nov 17, 2026) | $16.40 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 20.9x and 5.8x. Its year-end P/S ranged from 5.1x to 36.2x from 2018 to 2025.
| P/S Ratio | 20.9x |
|---|---|
| Forward P/S | 33.5x |
| P/B Ratio | 5.8x |
Price Statistics
The stock is down 18.29% over 52 weeks and trades 25.83% below its 50-day average.
| Beta (1Y) | 1.59 |
|---|---|
| 52-Week Change | -18.29% |
| 1-Month Change | -25.93% |
| 3-Month Change | -45.96% |
| 6-Month Change | -27.91% |
| 5-Year Change | -45.60% |
| Total Return (1Y) | -18.29% |
| Total Return (3Y CAGR) | +4.21% |
| Total Return (5Y CAGR) | -17.75% |
| Return vs SPY (1Y) | -30.33% |
| Max Drawdown (1Y) | -48.05% |
| Max Drawdown (3Y) | -65.96% |
| Sharpe Ratio (1Y) | -0.33 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $22.11 |
| 200-Day Average | $24.42 |
| 52-Week Range | $16.76 to $31.73 |
| RSI (14 Days) | 31.2 |
| Average Volume (20 Days) | 2.31M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.34x current liabilities, and total debt is 0.28x shareholder equity.
| Current Ratio | 3.34x |
|---|---|
| Quick Ratio | 3.34x |
| Debt / Equity | 0.28x |
| Interest Coverage | -40.18x |
Returns and Efficiency
Return on invested capital is -75.91% over the last 12 months, against a 5-year average of -37.34%.
| Return on Equity (ROE) | -126.54% |
|---|---|
| Return on Assets (ROA) | -55.38% |
| Return on Invested Capital (ROIC) | -75.91% |
| Return on Capital Employed (ROCE) | -71.41% |
| ROE (5Y Average) | -43.02% |
| ROA (5Y Average) | -20.03% |
| ROIC (5Y Average) | -37.34% |
| Asset Turnover | 0.11x |
Scores
RCUS has an Altman Z-Score of -1.39, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.39 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 0 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $100.00M over the last 12 months is down 58.33% from the 12 months before.
| Revenue | $100.00M |
|---|---|
| Revenue Growth (YoY) | -58.33% |
| Gross Profit | $100.00M |
| Operating Income | -$475.00M |
| Pretax Income | -$453.00M |
| Net Income | -$453.00M |
| EBITDA | -$442.00M |
| EBIT | -$442.00M |
| Reported EPS (TTM) | -$3.63 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 43.77% of the $818.00M in total assets.
| Cash and Equivalents | $151.00M |
|---|---|
| Total Debt | $102.00M |
| Net Cash | $49.00M |
| Net Cash Per Share | $0.38 |
| Working Capital | $465.00M |
| Shareholder Equity | $358.00M |
| Book Value Per Share | $2.81 |
| Total Assets | $818.00M |
| Total Liabilities | $460.00M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$465.00M |
|---|---|
| FCF Per Share | -$3.71 |
| Depreciation and Amortization | $20.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -475.00%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -475.00% |
| Pretax Margin | -453.00% |
| Net Margin | -453.00% |
| EBITDA Margin | -442.00% |
| EBIT Margin | -442.00% |
Growth
Revenue grew 30.16% a year over 3 years.
| Revenue Growth (3Y CAGR) | +30.16% |
|---|---|
| Revenue Growth (5Y CAGR) | +25.93% |
| Book Value Per Share Growth (2Y CAGR) | -2.34% |
| Tangible Book Per Share Growth (2Y CAGR) | -2.34% |
Dividends and Yields
RCUS does not pay a dividend.
| Buyback Yield | -14.93% |
|---|---|
| Shareholder Yield | -14.93% |
Peer Position
Against 8 similar companies, RCUS has the 2nd highest P/S.
P/S RatioPeer median 8.1x
ROICPeer median -27.46%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +25.30%
| P/S Ratio | 20.9x vs 8.1x median |
|---|---|
| ROIC | -75.91% vs -27.46% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -58.33% vs +25.30% median |
Analyst Forecast
Consensus estimates put revenue growth at -56.83% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -56.83% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RCUS
What is RCUS's market cap?
Arcus Biosciences has a market cap of $2.43B. Its enterprise value, which adds debt and subtracts cash, is $2.38B.
How many shares of RCUS are outstanding?
Arcus Biosciences has 127.40M shares outstanding. The count is up 19.62% from a year earlier.
Does RCUS pay a dividend?
No. Arcus Biosciences does not pay a dividend.
How much debt does RCUS have?
Arcus Biosciences has $102.00M of total debt and $151.00M of cash and equivalents, a net cash position of $49.00M.
RCUS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors